Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade

• Ipilimumab achieved an ORR of 23% in patients with multiply relapsed cHL, failing to meet the primary endpoint of the trial. • Expression of immune checkpoints within the cHL microenvironment may not be sufficient to predict efficacy of targeted immunotherapies.

Authors

Institutions

Publication Details

Journal
Blood Neoplasia
Published
2025-10-10
DOI
https://doi.org/10.1016/j.bneo.2025.100173
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade

Austin I. Kim, Jeremy S. Abramson, Justin Paul Kline, Robert Allyn Redd et al.
Blood Neoplasia
Lymphoma Diagnosis and Treatment
article

Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade

Austin I. Kim, Jeremy S. Abramson, Justin Paul Kline, Robert Allyn Redd, Jennifer R. Brown, Oreofe Olukemi Odejide, Margaret A. Shipp, Caron Alyce Jacobson, Erin Michelle Parry, Philippe A. Armand, Inhye E. Ahn, Scott J. Rodig, Matthew Steven Davids, Reid W. Merryman, Christine E. Ryan, Kathleen L. Pfaff, Eric D. Jacobsen, Ann Steward LaCasce, Jennifer Leigh Crombie, Hannah Lee, David Christopher Fisher, Emma J Welsh, Mikaela M. McDonough, Harrison Olszewski
article en

Abstract

• Ipilimumab achieved an ORR of 23% in patients with multiply relapsed cHL, failing to meet the primary endpoint of the trial. • Expression of immune checkpoints within the cHL microenvironment may not be sufficient to predict efficacy of targeted immunotherapies.

Blood NeoplasiaVol. 3(1)
Brigham and Women's Hospital (US), University of Chicago (US), Massachusetts General Hospital (US), Dana-Farber Cancer Institute (US)
Openalex Percentile: Top 60%
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.